Executives at Enovis, Smith-Midland Buy Shares Near Lows; Insiders at Illumina, Okta Sell

Recent securities filings disclosed a wave of insider trading activity, revealing executives at some companies buying into recent stock weakness while insiders at others sold substantial positions near multi-year highs.

Notable Insider Purchases

Executives at Enovis Corp. (ENOV) made significant purchases as the stock traded near its 52-week low. According to filings, CEO Damien McDonald acquired 13,035 shares for approximately $249,620, and Chief Administrative Officer Oliver Engert purchased shares totaling $149,970. These buys came after the stock had declined about 25% over the past week.

Similarly, Smith-Midland Corp. (SMID) saw buying from two insiders as its stock hovered near a 52-week low. CEO Ashley B. Smith purchased 2,000 shares for $53,740, while Director Matthew I. Smith also acquired 2,000 shares for $54,300 in separate open-market transactions.

In the biotechnology sector, a director at Atara Biotherapeutics (ATRA), Brian N. Cherry, purchased 104,166 shares for nearly $1 million. This transaction stands out as it follows an 81% surge in the company's stock price over the last six months.

Significant Insider Sales

A director and 10% owner at Illumina (ILMN), Keith A. Meister of Corvex Management, sold a total of $57.2 million worth of common stock. The sales, disclosed in a Form 4 filing, occurred in multiple transactions as the stock traded near its 52-week high after an 80% return over the previous year.

Ad

At Okta, Inc. (OKTA), Chief Financial Officer Brett Tighe sold 80,000 shares for a total of $12.9 million. The transactions were executed under a pre-arranged Rule 10b5-1 trading plan established in April 2026. The sale followed a 90% rise in Okta's share price over the past year.

Executives at Krystal Biotech, Inc. (KRYS) also sold large stakes under 10b5-1 plans. CEO Krish S. Krishnan and President of R&D Suma Krishnan each sold shares worth approximately $8.98 million. These sales took place as the stock traded near its 52-week high, having delivered a 139% return over the past year.

Context for Investors

Insider trading activity is closely monitored by investors for signals about a company's future prospects. Purchases, particularly by multiple executives when a stock price is depressed, can suggest confidence in a potential recovery.

Conversely, insider sales do not always indicate a negative outlook. Many executives sell shares for personal financial management, diversification, or tax planning, often through pre-scheduled 10b5-1 plans to avoid conflicts of interest. However, a pattern of heavy selling, especially at market peaks, is a data point investors often consider alongside other fundamental analysis.